DiaMedica Therapeutics Priced, Nasdaq: DMAC

Phase 2 biotech targeting acute ischemic stroke and chronic kidney disease.

Industry: Health Care

Latest Trade: $3.59 0.00 (0.0%)

First Day Return: n/a

Return from IPO: -10.3%

Industry: Health Care

We are a clinical stage biopharmaceutical company primarily focused on the development of novel recombinant proteins. Our goal is to use our patented and licensed technologies to establish our company as a leader in the development and commercialization of therapeutic treatments for novel recombinant proteins to treat neurological and kidney diseases. Our current primary focus is on acute ischemic stroke (AIS) and chronic kidney disease (CKD). We plan to advance DM199, our lead drug candidate, through required clinical trials to create shareholder value by establishing its clinical and commercial potential as a therapy for AIS and CKD. We have not generated any revenues from product sales. Since our inception, we have financed our operations from public and private sales of equity, the exercise of warrants and stock options, interest income on funds available for investment, and government grants and tax credits. We have incurred losses in each year since our inception.
more less
IPO News for DiaMedica Therapeutics
more
IPO Data
IPO File Date 11/09/2018
Offer Price $4.00
Price Range $4.00 - $5.00
Offer Shares (mm) 4.1
Deal Size ($mm) $16
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 12/06/2018
Offer Price $4.00
Price Range $4.00 - $5.00
Offer Shares (mm) 4.1
Deal Size ($mm) $16
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Minneapolis, MN
Founded 2000
Employees 11
Website www.diamedica.com